Melanotan II structure
|
Common Name | Melanotan II | ||
---|---|---|---|---|
CAS Number | 121062-08-6 | Molecular Weight | 1024.178 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C50H69N15O9 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A |
Use of Melanotan IIMelanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning. |
Name | Melanotan II acetate salt |
---|---|
Synonym | More Synonyms |
Description | Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning. |
---|---|
Related Catalog | |
In Vitro | Melanotan (MT)-II is a potent non-selective melanocortin receptor agonist with high affinity for MC1, MC3, MC4, and MC5 receptor subtypes which are involved in the regulation of a number of physiological systems such as the pigmentary system, energy homoeostasis, sexual functioning, the immune system, inflammation, and the cardiovascular system[1]. |
In Vivo | Melanotan (MT)-II exerts a dose-dependent inducer activity on erection by eliciting erectile events and shortening latency of the first erectile event to occur. Erectile responses elicited by cavernous nerve stimulation are increased after i.v. melanotan (MT)-II (1 mg/kg), thereby exerting facilitator effect on erection[2]. Melanotan (MT)-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Melanotan (MT)-II significantly enhances the recovery of sensory function following a crush lesion of the sciatic nerve in the rat at a dose of 20 μg/kg per 48 h, s.c., but not at a dose of 2 or 50 μg/kg[3]. Melanotan (MT)-II is a potent initiator of penile erection in men with erectile dysfunction[4]. Melanotan (MT)-II reduces food intake and body weight and invokes thermogenic responses in a mouse model[5]. |
Animal Admin | Rats: To investigate the inducer activity on erection, melanotan (MT)-II or vehicle (saline) is acutely injected i.v., i.t. or within the PVN after a 5 min baseline recording period is obtained. ICP and MAP are then recorded for a 60 min period after saline or melanotan (MT)-II delivery. I.v. injections (three doses; 0.1, 0.3, and 1 mg/kg in saline) are performed with a catheter inserted in the jugular vein[2]. Mice: Melanotan (MT)-II (0.1 and 0.2 nM) or vehicle (artificial cerebrospinal fluid) is administered. SPA is recorded continuously every 5 min. Food intake measurements are taken 6 and 24 h postinjection. Body weight is measured every 24 h. Chow and water are available ad libitum. A 48-h interval occurrs between drug treatments[5]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C50H69N15O9 |
Molecular Weight | 1024.178 |
Exact Mass | 1023.540283 |
PSA | 382.26000 |
LogP | -1.27 |
Index of Refraction | 1.683 |
Storage condition | −20°C |
Water Solubility | H2O: 5 mg/mL, soluble |
~30% Melanotan II CAS#:121062-08-6 |
Literature: Al-Obeidi, Fahad; Castrucci, Ana M. de L.; Hadley, Mac E.; Hruby, Victor J. Journal of Medicinal Chemistry, 1989 , vol. 32, # 12 p. 2555 - 2561 |
~%
Detail
|
Literature: Journal of Medicinal Chemistry, , vol. 32, # 12 p. 2555 - 2561 |
~%
Detail
|
Literature: Journal of Medicinal Chemistry, , vol. 40, # 17 p. 2740 - 2749 |
(3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-(3-carbamimidamidopropyl)-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide |
1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide, 15-[[(2S)-2-(acetylamino)-1-oxohexyl]amino]-6-[3-[(diaminomethylene)amino]propyl]-12-(1H-imidazol-4-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-9-(phenylmethyl)-, (3S,6S,9R,12S,15S,23S)- |
(3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-(3-carbamimidamidopropyl)-12-(1H-imidazol-4-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide |
(3S,6S,9R,12S,15S,23S)-15-[(N-acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-(1H-imidazol-4-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide |
1,4,7,10,13,18-Hexaazacyclotricosane-23-carboxamide, 15-[[(2S)-2-(acetylamino)-1-oxohexyl]amino]-6-[3-[(diaminomethylene)amino]propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-9-(phenylmethyl)-, (3S,6S,9R,12S,15S,23S)- |
MFCD01318793 |
1,4,7,10,13,18-Hexaazacyclotricosane-23-carboxamide, 15-[[(2S)-2-(acetylamino)-1-oxohexyl]amino]-6-[3-[(aminoiminomethyl)amino]propyl]-12-(1H-imidazol-4-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-9-(phenylmethyl)-, (3S,6S,9R,12S,15S,23S)- |
(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide |
(3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylene)amino]propyl}-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide |
1,4,7,10,13,18-Hexaazacyclotricosane-23-carboxamide, 15-[[(2S)-2-(acetylamino)-1-oxohexyl]amino]-6-[3-[(aminoiminomethyl)amino]propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-9-(phenylmethyl)-, (3S,6S,9R,12S,15S,23S)- |
Melanotan II Acetate |
Ac-[Nle4Asp5D-Phe7Lys10]α-MSH-(4-10)-NH2 |
Melanotan (MT)-II |